Accelerated atherogenesis and neointima formation in heparin cofactor II–deficient mice
Open Access
- 15 December 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (13), 4261-4267
- https://doi.org/10.1182/blood-2007-04-086611
Abstract
Heparin cofactor II (HCII) is a plasma protein that inhibits thrombin when bound to dermatan sulfate or heparin. HCII-deficient mice are viable and fertile but rapidly develop thrombosis of the carotid artery after endothelial injury. We now report the effects of HCII deficiency on atherogenesis and neointima formation. HCII-null or wild-type mice, both on an apolipoprotein E–null background, were fed an atherogenic diet for 12 weeks. HCII-null mice developed plaque areas in the aortic arch approximately 64% larger than wild-type mice despite having similar plasma lipid and glucose levels. Neointima formation was induced by mechanical dilation of the common carotid artery. Thrombin activity, determined by hirudin binding or chromogenic substrate hydrolysis within 1 hour after injury, was higher in the arterial walls of HCII-null mice than in wild-type mice. After 3 weeks, the median neointimal area was 2- to 3-fold greater in HCII-null than in wild-type mice. Dermatan sulfate administered intravenously within 48 hours after injury inhibited neointima formation in wild-type mice but had no effect in HCII-null mice. Heparin did not inhibit neointima formation. We conclude that HCII deficiency promotes atherogenesis and neointima formation and that treatment with dermatan sulfate reduces neointima formation in an HCII-dependent manner.Keywords
This publication has 38 references indexed in Scilit:
- Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II–deficient miceJCI Insight, 2007
- Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: Implications for a possible physiological function of heparin cofactor IIBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2005
- Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient miceBlood, 2004
- High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stentingThrombosis and Haemostasis, 2004
- A Model of Primary Atherosclerosis and Post-Angioplasty Restenosis in MiceThe American Journal of Pathology, 2003
- Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-β in carotid artery of atherosclerotic rabbitsAtherosclerosis, 2003
- Inflammation in atherosclerosisNature, 2002
- Altered Dermatan Sulfate Structure and Reduced Heparin Cofactor II-stimulating Activity of Biglycan and Decorin from Human Atherosclerotic PlaquePublished by Elsevier BV ,2000
- Colocalization of Thrombin, PAI-1, and Vitronectin in the Atherosclerotic Vessel WallArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Vascular Localization of the Heparin-binding Serpins Antithrombin, Heparin Cofactor II, and Protein C InhibitorClinical and Applied Thrombosis/hemostasis, 1996